病院獲得ABSSIはプロセスコンポーネントセグメントで重要な市場シェアを保持することが期待されています

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場力学

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

    • 4.3.1 政府による厳しい規制政策と特許切れ

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 感染症の種類別

    • 5.1.1 病院後天性ABSSI

    • 5.1.2 コミュニティが取得したABSSI

  • 5.2 投与経路別

    • 5.2.1 オーラル

    • 5.2.2 非経口

    • 5.2.3 トピカル

  • 5.3 流通チャネル別

    • 5.3.1 病院内薬局

    • 5.3.2 小売薬局

    • 5.3.3 オンライン薬局

  • 5.4 地域別

    • 5.4.1 北米

      • 5.4.1.1 米国
      • 5.4.1.2 カナダ
      • 5.4.1.3 メキシコ

    • 5.4.2 ヨーロッパ

      • 5.4.2.1 ドイツ
      • 5.4.2.2 英国
      • 5.4.2.3 フランス
      • 5.4.2.4 イタリア
      • 5.4.2.5 スペイン
      • 5.4.2.6 その他ヨーロッパ

    • 5.4.3 アジア太平洋

      • 5.4.3.1 中国
      • 5.4.3.2 日本
      • 5.4.3.3 インド
      • 5.4.3.4 オーストラリア
      • 5.4.3.5 韓国
      • 5.4.3.6 その他アジア太平洋

    • 5.4.4 中東・アフリカ

      • 5.4.4.1 GCC地域
      • 5.4.4.2 南アフリカ
      • 5.4.4.3 その他中東・アフリカ

    • 5.4.5 南米

      • 5.4.5.1 ブラジル
      • 5.4.5.2 アルゼンチン
      • 5.4.5.3 その他南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Paratek Pharmaceuticals, Inc

    • 6.1.2 Melinta Therapeutics, Inc

    • 6.1.3 Allergan plc

    • 6.1.4 Merck & Co., Inc

    • 6.1.5 AccordHealthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)

    • 6.1.6 Sandoz Inc. (a subsidiary of Novartis)

    • 6.1.7 Glenmark Pharmaceuticals Ltd

    • 6.1.8 Cadila Healthcare Ltd

    • 6.1.9 Teva Pharmaceutical Industries Ltd

    • 6.1.10 Pfizer Inc

    • 6.1.11 Cumberland pharmaceutical inc

• 7 市場機会と今後の動向

The Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is expected to grow at a registered CAGR of 9.9% during the forecast period (2022-2027).

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the acute bacterial skin and skin structure infection (ABSSSI) market. However, according to the study titled "Hospital-acquired Skin and Skin-structure Infection in COVID-19 Infected Patient with Prolonged Hospitalization" published in the Acta Medica Indonesia in January 2021, bacterial skin and skin structure infections are worsened in the COVID-19 patient. They are required to prolong hospitalization rise in the treatment options demand, thereby anticipating market growth during COVID-19. Thus, the acute bacterial skin and skin structure infection (ABSSSI) market was significantly impacted by COVID-19.

The rising prevalence and awareness of acute bacterial skin and skin structure infection, as well as increased research and development activities by pharmaceutical and biopharmaceutical companies to supply new products and novel treatments, all contribute to the global ABSSSI market's growth.

Two of the most common bacteria that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S. aureus. Gram-negative bacteria, other Streptococcus species, and Enterococcus faecalis are less common causes. According to the study titled "Management of Acute Bacterial Skin and Skin Structure Infections in India: Are We Equipped to Meet the Challenges of the Growing Menace of Methicillin-Resistant Staphylococcus aureus?" published in the International Surgery Journal in July 2020, Staphlococcus aureus (Staphylococcus aureus) is a Gram-positive facultative anaerobic bacteria that colonize human skin and nasal passages. Invasive S. aureus infections have become more common in recent decades and are linked to poor outcomes and high mortality rates. S. aureus causes nearly one-third of all acute bacterial skin and skin structure infections, with methicillin-resistant Staphylococcus aureus (MRSA) accounting for most of these infections.

However, growing pipeline development activity and rising research and development expenditure by pharmaceutical and biotechnology companies are anticipated to drive the market over the forecast period. For instance, as per the clinicaltrials.gov in May 2021, Ceftobiprole Medocarial under Phase III trials is an effective treatment option for acute bacterial skin and skin structure infections. Moreover, according to the same source posted on October 2020, an intravenous formulation of TNP-2092 from TenNor Pharmaceutical Limited is also under clinical development for treating acute bacterial skin and skin structure infections (ABSSSI).

Furthermore, growing product launches and various activities by the key market players such as mergers and acquisitions, collaborations, and partnerships are anticipated to drive the market. For instance, in March 2021, Kimyrsa (oritavancin; Melinta Therapeutics) was approved by the Food and Drug Administration (FDA) to treat adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms. In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, reported the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion.

Thus, all these factors are expected to boost the market over the forecast period.

Key Market Trends

Hospital Acquired ABSSI is is Expected to Hold Significant Market Share in the Process Component Segment

Infections acquired in a healthcare setting that was not present before the contact are known as healthcare-associated infections (HCAIs). They may cause (or prolong) stays in acute care hospitals, increase medical and economic burdens, and cause morbidity and mortality. For instance, according to the study titled "Update on the Epidemiology of Healthcare-Acquired Bacterial Infections: Focus on Complicated Skin and Skin Structure Infections," published in the Journal of Antimicrobial Chemotherapy in November 2021, Adult inpatients in National Health Service hospitals in England are estimated to have 834,000 Healthcare-associated infections (HCAIs) each year, accounting for 7.1 million occupied hospital bed days (21 percent of total annual bed days) and a EUR 2.7 billion economic burden.

Furthermore, according to the same source, the prevalence of HCAI is estimated to be 6.0 percent. The most common infections were skin and soft tissue infections (SSTIs), which included surgical site infections (SSIs). Patients in intensive care units had the highest rate of hospital-acquired ABSSSI. Thus growing prevalence of hospital-acquired infection is expected to boost the segment growth.

However, various strategic activities by the key market to boost the market include product launches, pipeline development, and merger and acquisition. For instance, in July 2021, Delafloxacin was approved in the United Kingdom to treat acute bacterial skin and skin structure infections (ABSSSI) in adults when other antibacterial agents are considered inappropriate for the initial treatment of these infections.

North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period

North America will continue to dominate the acute bacterial skin and skin structure infection market during the forecast period due to extensive research and development activity, R&D spending, product pipeline, and novel product launches. For instance, as per the ClinicalTrials.gov posted on January 2020, study title "Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)"under the clinical development for the drug Dalbavancin from the allergen pharmaceutical in the United States. Thus, the number of drugs under clinical trials is expected to increase the product launch over the projected period of anticipated market growth.

However, the growing product pipeline and product approval by regulatory authorities are expected to boost the market over the forecast period. For instance, in July 2021, the Food and Drug Administration (FDA) expanded the approval of Dalvance (dalbavancin) to include treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms in pediatric patients. Previously, the treatment was only approved for adults 18 and older. Additionally, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), a 30-minute intravenous (IV) therapy in Canada for acute bacterial skin and skin structure infections (ABSSSI) that can be administered as a single- or two-dose regimen.

Thus, all such factors are expected to boost the market in North America over the forecast period.

Competitive Landscape

The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. However, with technological advancements and product innovations, mid-size to smaller companies increase their market presence by introducing new products at lower prices. Some of the market players are Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd), and Cadila Healthcare Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Rising Prevalence and Awareness of Acute Bacterial Skin and Skin Structure Infection

    • 4.2.2 Increasing Pipeline Development Activities

    • 4.2.3 Rising Healthcare Spending Across the World

  • 4.3 Market Restraints

    • 4.3.1 Stringent Regulatory Policies by Government Bodies, and Patent Expiration

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type of Infection

    • 5.1.1 Hospital Acquired ABSSI

    • 5.1.2 Community acquired ABSSI

  • 5.2 By Route of Administration

    • 5.2.1 Oral

    • 5.2.2 Parenteral

    • 5.2.3 Topical

  • 5.3 By Distribution Channel

    • 5.3.1 Hospital Pharmacies

    • 5.3.2 Retail Pharmacies

    • 5.3.3 Online Pharmacies

  • 5.4 Geography

    • 5.4.1 North America

      • 5.4.1.1 United states
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico

    • 5.4.2 Europe

      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe

    • 5.4.3 Asia-Pacific

      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific

    • 5.4.4 Middle-East and Africa

      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa

    • 5.4.5 South America

      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Paratek Pharmaceuticals, Inc

    • 6.1.2 Melinta Therapeutics, Inc

    • 6.1.3 Allergan plc

    • 6.1.4 Merck & Co., Inc

    • 6.1.5 AccordHealthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)

    • 6.1.6 Sandoz Inc. (a subsidiary of Novartis)

    • 6.1.7 Glenmark Pharmaceuticals Ltd

    • 6.1.8 Cadila Healthcare Ltd

    • 6.1.9 Teva Pharmaceutical Industries Ltd

    • 6.1.10 Pfizer Inc

    • 6.1.11 Cumberland pharmaceutical inc

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS